On the sample size of clinical trials by Papageorgiou, Spyridon N
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
On the sample size of clinical trials
Papageorgiou, Spyridon N
DOI: https://doi.org/10.1080/14653125.2018.1501929
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-169520
Journal Article
Accepted Version
Originally published at:
Papageorgiou, Spyridon N (2018). On the sample size of clinical trials. Journal of Orthodontics,
45(3):210-212.
DOI: https://doi.org/10.1080/14653125.2018.1501929
STATISTICAL CORNER 
On the sample size of clinical trials 
 
Spyridon N. Papageorgiou 
Clinic of Orthodontics and Pediatric Dentistry, Center of Dental Medicine, University of Zurich, 
Zurich, Switzerland 
 
ORCID Spyridon N. Papageorgiou http://orcid.org/0000-0003-1968-3326 
 
CONTACT Spyridon N. Papageorgiou Clinic of Orthodontics and Pediatric Dentistry, Center of 
Dental Medicine, University of Zurich, Plattenstrasse 11, Zurich CH 8032, Switzerland; 
snpapage@gmail.com. 
 
Words in text: 959 
 
Disclosure statement 
No potential conflict of interest was reported by the author. 
 
  
MANUSCRIPT 
Theoretical scenario 
Clinical trials in orthodontics often have as primary outcome the total duration of fixed appliance 
treatment from bonding to debonding of the appliances. This is one of the most clinically relevant 
outcomes to the patient or the orthodontist and prolonged treatment times are associated with 
adverse effects like patient burnout and the development of white spot lesions or root resorption. 
Data from existing randomized trials indicate that the outcome of treatment duration is normally 
distributed and that an average duration of 20 months with a Standard Deviation (SD) of about 5 
months might not be an unrealistic estimate to expect—although large variability in treatment 
times exists. 
A group of orthodontic researchers plan to conduct a two-group parallel randomized 
clinical trial to assess the effect of corticotomy on the reduction of overall treatment duration. 
However, disheartened from the large sample size needs yielded by a formal statistical sample 
size calculation, they arbitrarily decide to recruit a total of 20 patients in the two treatment groups 
and try to pass the study as a ‘pilot study’. Their justification is that as this is a randomized trial 
the possibility of bias will be low and their results will still be robust, despite the objectively small 
sample size. 
After completing their trial and collecting data, they routinely check for normal distribution 
of treatment duration with the Shapiro-Wilk test, which gives them a P value of 0.01 that 
indicates absence of normality. Therefore, they adjust their descriptive and inferential statistics 
to the non-normal distribution. Finally, they conclude that although this is a pilot study with small 
sample, the randomized nature of the study means that its results are robust and in low risk of 
bias. 
 
Which of the following statements are correct, if any: 
(a) Having a small sample in a trial cannot affect the average treatment duration measured. 
(b) Having a small sample in a trial might affect the precision of the estimated results. 
(c) Having a small sample in a trial cannot affect the ‘normality’ (or lack thereof) of the trial’s 
outcome. 
(d) Randomization can safeguard against any limitations associated with a small sample size. 
 
Discussion 
To illustrate the first statement, we generate a large parent sample of 200 patients that should 
correspond to the ‘true’ mean duration of 20 months and an SD of 5 months. As all samples are 
subject to a certain variability, we end up with the sample of 200 patients having a mean of 19.4 
months and an SD of 5.4 months, which is pretty close to what we initially aimed. If we now draw 
random trial samples of 20 patients each from the parent sample, we can see an interesting 
finding in Figure 1. Although many of the drawn samples (blue boxes) are relative close to the 
‘true’ average duration of 20 months (green box), the mean values of the trials vary 
considerably—like sample H that has a mean duration of 18.2 months. This is exaggerated even 
more if we further reduce the recruited sample size from 20 to 10 patients, where the mean 
values of the small trials (red boxes) are generally more far away from the true mean (green 
box). We see therefore signs of bias of the estimator, in which the sample size of a trial together 
with pure chance can influence the results that are actually measured in a trial. Therefore, 
statement A is false. 
 Furthermore, we can assess the precision of the measured results in the drawn samples 
by calculating the 95% Confidence Intervals (CIs) of the mean treatment duration in each trial. 
We would then see that the parent sample A has a very narrow 95% CI spanning only about 1.5 
month (19.2 to 20.7 months), which indicates high precision (Figure 1). On the other side, trials 
with 20 patients (coloured blue) have much wider 95% CIs of at least 4 months. This is again 
further exaggerated in trials with 10 patients (coloured red), where the 95% CIs span almost 10 
months! We see therefore, that even in a perfectly random setting, the sample size of a trial is 
closely related to the trial’s precision—and statement B is correct. 
In order to assess the truth of statement C, one method would be to plot the distributional 
histograms of the drawn trial samples and perform the Shapiro-Wilk test to formally assess the 
normal distribution of treatment duration. As Figure 2 indicates, the distribution of the parent 
sample A resembles that of a normal distribution (top) and this is confirmed by a non-significant 
Shapiro-Wilk test (P>0.05). On the other side, a great variability in the outcome distribution can 
be seen among both trials with 20 patients (middle row) and with 10 patients (bottom row). Also, 
formal testing for normality with the Shapiro-Wilk test gives diverse results and indicates that 
some trials from the middle or bottom row have non-normally distributed outcome (P<0.05). This 
would lead the authors of the trial to conclude that treatment duration is not normally distributed 
and chose a different statistical analysis plan than better fits normally-distributed data. 
Therefore, statement C is wrong. 
 Finally, randomization in a trial is employed to ensure the baseline equivalence of the 
randomized groups for all known or unknown factors that could potentially affect treatment 
duration. This means that any difference in the final treatment duration of the randomized groups 
could be potentially attributed to their different treatment protocol. Randomization cannot 
safeguard from the limitations of having a small sample, which can ultimately affect the results of 
the trial and their validity. This is the reason why the CONSORT (Consolidated Standards of 
Reporting Trials) statement (Moher et al. 2010) has distinct items for describing sample size 
calculation and randomization, as these are two separate procedures independent of each other. 
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Figure 1. Results of the same hypothetical trial with a set mean treatment duration of 20 months and a standard
deviation of 5 months. The trial’s sample size varies between 200, 20, and 10 patients and new samples are randomly
drawn. The results of each trial are expressed as the mean with its 95% Confidence Interval (CI).
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Figure 2. Distributional histograms of the samples from Figure 1. The normal distribution in each
case is checked with a P value from the Shapiro-Wilk test.
